Skip to content
PatentBrief
Get alertsTop ↑

Making Better CAR-T Cells to Fight Lymphoma

This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.

Granted 2026ActiveExpires 2041Owned by Kite PharmaInvented by John Rossi, Jenny Jiyun Kim, Adrian Bot + 3 more

Original patent title: “Chimeric antigen receptor T cell therapy”

Plain-English explanation by SahiLast reviewed · November 1, 2026

This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects. Granted to Kite Pharma in 2026 with 15 claims, and it is expected to expire in 2041.

Coverage

What does this patent actually cover?

The patent claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more → a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).

The gap

What does this patent NOT cover?

  • Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover CAR-T cell therapies targeting antigens other than CD19 (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1).
  • Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 3).
  • Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 12630603
StatusActive
FieldBiotech & Medicine
AssigneeKite Pharma
InventorsJohn Rossi, Jenny Jiyun Kim, Adrian Bot and 3 others
Filed2021
Granted2026
Expires2041
Claims15
Times cited0
LitigationNone on record
Value · $54K–$173KModest

What made this novel

The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.

The Patent Drawing

Representative patent drawing for Chimeric antigen receptor T cell therapy (US 12630603)
Representative figure · US 12630603All figures on Google Patents →
Chimeric antigen receptor T ce…(Primary claim)biotechpharmaceuticalgene editingoncologyimmunology

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Yescarta (axicabtagene ciloleucel)

02

Tecartus (brexucabtagene autoleucel)

03

Other anti-CD19 CAR-T cell therapies

04

Personalized cancer immunotherapies

Why it matters

The bigger picture

Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.

Filed

February 20, 2021

Granted

May 19, 2026

Market context

Who's building on this

Companies in this space

Kite Pharma, a Gilead company and the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more → of this patent, is a leader in CAR-T cell therapy, with approved products like Yescarta and Tecartus. Other major players like Novartis (Kymriah), Bristol Myers Squibb (Breyanzi, Abecma), and Johnson & Johnson are also actively developing and refining CAR-T cell manufacturing and therapies. These companies are continually researching ways to improve the efficacy and safety of cell-based immunotherapies.

Market impact

This patent aims to refine existing CAR-T cell therapies, which have already created a new category of personalized cancer treatment. If successful, it could lead to next-generation CAR-T products with better safety profiles and higher long-term success rates, potentially expanding the eligible patient population and further solidifying CAR-T's role in oncology. It could also influence manufacturing standards for future cell therapies, driving innovation in how these complex treatments are prepared and delivered to patients.

Claim 1 — Plain English

What this patent covers

The patent claims a method for making an anti-CD19 Chimeric Antigen Receptor (CAR)-T cell immunotherapy product that works better and has fewer severe side effects for Non-Hodgkin's Lymphoma (NHL) patients. It involves taking a patient's T cells and, during the manufacturing process, specifically increasing or maximizing the percentage of "naïve" CD4+ and CD8+ T cells, identified by the CD45RA+ CCR7+ markers (Claim 1). This optimized product must contain at least 20x10^6 of these specific naïve T cells, adjusted for the patient's tumor size (Claim 1). For example, a patient with relapsed/refractory large B-cell lymphoma (Claim 3) would receive a CAR-T infusion engineered with a higher proportion of these specific T cells, aiming for a more lasting response and less severe cytokine release syndrome or neurological issues (Claim 1).

The clever bit

The clever bit is recognizing that not all T cells are equally effective in CAR-T therapy, and that enriching for a specific "naïve" T cell phenotype (CD45RA+ CCR7+) during manufacturing can lead to both better, more lasting cancer responses and fewer severe side effects like cytokine release syndrome.

What it does not cover

  • Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).
  • Does not cover CAR-T cell manufacturing methods that do not ensure at least 20x10^6 of these specific naïve T cells in the final product (Claim 1).
  • Does not cover CAR-T cell therapies targeting antigens other than CD19 (Claim 1).
  • Does not cover CAR-T cell therapies for cancers other than Non-Hodgkin's Lymphoma, advanced-stage indolent NHL, large B-cell lymphoma, or Mantle Cell Lymphoma (Claim 3).
  • Does not cover methods of simply administering CAR-T cells without a specific manufacturing step to enrich for naïve T cells.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Early stage

Citation count

0/40

No citations yet

Claim breadth

10/20

Broad claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

20/20

Granted within 5 years

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$54K – $173K

Midpoint $108K · 14.2 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

15 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

8

earlier patents this invention cites as foundations

View prior art →

Cite this patent

Rossi, J., Kim, J. J., Bot, A., GO, W., Plaks, V., & CHOU, S. (2026). Making Better CAR-T Cells to Fight Lymphoma (U.S. Patent No. 12,630,603). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12630603/chimeric-antigen-receptor-t-cell-therapy-12630603

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US12630603"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:biotech patents →pharmaceutical patents →gene editing patents →

Common Questions

Frequently Asked Questions

What does Making Better CAR-T Cells to Fight Lymphoma cover?

This patent describes a specific way to prepare anti-CD19 CAR-T cell therapy for lymphoma patients, by increasing the number of certain "naïve" T cells to improve treatment success and reduce side effects.

Who owns patent US 12630603?

Kite Pharma owns this patent, granted in 2026.

When does this patent expire?

This patent is expected to expire on February 20, 2041, when the invention enters the public domain.

What problem does this patent solve?

Chimeric Antigen Receptor (CAR)-T cell therapy is a powerful, personalized treatment for certain blood cancers, but it can have severe side effects and not all patients respond durably. This patent addresses these challenges by proposing a manufacturing method to create a more effective and safer CAR-T product. By focusing on specific T cell types, it aims to improve patient outcomes, making this advanced therapy more widely applicable and tolerable.

What does this patent NOT cover?

Does not cover CAR-T cell therapies that do not specifically increase or maximize the percentage of CD4+ and CD8+ T cells with a CD45RA+ CCR7+ naïve phenotype (Claim 1).

Same assignee

More from Kite Pharma

View all →
US 12600775·2026

Treating a Specific Lymphoma with Modified T Cells

Patent monitoring

Get notified when Kite Pharma files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 1, 2026 · PatentBrief is not a law firm and this is not legal advice.